Precipio (PRPO) Peer Comparison

$30.41

$-0.45 (-1.44%)

As on 26-Aug-2026 16:00EDT

Market cap

$55 Mln

Revenue (TTM)

$27 Mln

P/E Ratio

--

P/B Ratio

3.6

Div. Yield

0 %

Edit

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	55	12,753	10,906	9,762	10,222
Revenue ($ Mln)	27	1,505	613	2,589	785
Net Profit ($ Mln)	-1.22	160.59	-188.05	222.40	41.54
Net Margin (%)	-4.42	10.67	-30.68	8.59	5.29
RoE (%)	-8.29	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	3.59	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	27.46	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	15.46	483.98	127.96	1,245.50	384.30
Gross Profit	10.71	942.44	393.22	1,343.60	347.62
Operating Expenses	13.54	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-1.55	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-1.22	203.83	-192.83	350.40	52.15
Provision for Tax	0.00	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-1.22	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	14.76	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	2.86	210.18	135.71	2,116.80	705.49
Current Liabilities	3.70	233.78	102.33	961.30	132.66
Total Liabilities	21.32	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	14.78	630.60	404.74	7,231.50	1,749.63
Current Assets	6.54	1,344.12	515.78	3,020.50	1,200.55
Total Assets	21.32	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	3.34	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	0.69	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.33	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	0.90	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-2.30	11.76	-22.53	8.98	1.79
ROE (%)	-8.29	10.86	-28.10	3.04	1.97
ROA (%)	-4.76	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-4.51	13.63	-30.58	-5.99	9.87
Net Margin (%)	-4.42	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	33.50	17.55	41.55	1.37	16.49
EBIT Growth (%)	26.90	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	32.54	8.72	-102.66	-30.32	400.42
EPS Growth (%)	46.06	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	7.68	17.33	-12.65	2.19	2.16

Valuation Ratios

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-101.61	68.93	-34.59	--	189.42
Price / Book Value	2.53	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	23.60	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.05	0.01	0.00	0.06	0.01
Current Ratio	1.77	5.75	5.04	3.14	9.05
Quick Ratio	1.56	3.86	4.46	2.33	7.64
Interest Coverage	51.63	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Precipio (PRPO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	8.30	12.65	22.67	17.06	20.09
Asset Turnover	1.08	0.74	0.59	0.24	0.26
Receivable days	21.13	46.54	60.95	65.39	72.41
Inventory Days	22.71	331.92	193.84	221.09	146.53
Payable days	23.94	26.16	60.19	37.02	29.05
Cash Conversion Cycle	19.90	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly